oxazolidin-2-one has been researched along with Lipid Metabolism, Inborn Error in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inazu, A; Mabuchi, H; Nohara, A | 1 |
| Barter, PJ; Kastelein, JJ; Nicholls, SJ; Rye, KA | 1 |
| Boekholdt, SM; Hovingh, GK; Ray, KK | 1 |
1 review(s) available for oxazolidin-2-one and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
Topics: Animals; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Humans; Lipid Metabolism, Inborn Errors; Oxazolidinones | 2014 |
2 other study(ies) available for oxazolidin-2-one and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome | 2015 |
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome | 2015 |